Drug Profile
Encapsulated tretinoin cream - Sol-Gel
Alternative Names: S6G5T-3; SIRS TLatest Information Update: 26 Jul 2022
Price :
$50
*
At a glance
- Originator Sol-Gel Technologies
- Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
- Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acne vulgaris
Most Recent Events
- 26 Jul 2022 Discontinued - Phase-III for Acne vulgaris (In adolescents, In children, In the elderly, In adults) in USA (Topical) (Sol-Gel Technologies pipeline, July 2022)
- 06 Feb 2020 Sol-Gel Technologies completes a phase I trial in Acne vulgaris (In adults, In adolescents, In children, In the elderly) in USA (Topical) (NCT04059523)
- 17 Dec 2019 Sol-Gel Technologies completes a phase III clinical trial in Acne vulgaris (In adults, In adolescents, In children, In the elderly) in USA (Topical) (NCT03761784)